Clinical Trials Browser

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03091491 2022-06-14

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

Phase 2 Terminated

31 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01820754 2021-02-26

TOP1201 IPI

Phase 2 Completed

24 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02716272 2021-02-10

MAPS2

Phase 2 Completed

125 enrolled

Other solid neoplasmThoracic

Mesothelioma

NCT03048474 2021-01-20

INITIATE

Phase 2 Completed

36 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03256136 2020-11-04

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Phase 2 Completed

9 enrolled 15 charts

Thoracic

Lung Neoplasms

NCT03823625 2020-03-25

SQUINT

Phase 2 Unknown

112 enrolled

Thoracic

Squamous-Cell Lung Cancer

NCT04250246 2020-01-31

NIBIT-ML1

Phase 2 Unknown

184 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT00527735 2018-07-18

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Phase 2 Completed

334 enrolled 29 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT01331525 2016-04-14

ICE

Phase 2 Completed

42 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Small Cell Lung Carcinoma

NCT01471197 2014-05-12

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

FLINN

REVIVE

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

CheckMate-1533

NIVIPI-Brain

TOP2101

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

RAD-IO

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

G360-IIT

CheckMate 6DW

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

ATLAS

NA_00092076

TOP1705

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

GALAXY 3

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

STIMULI

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

CheckMate 592

NIPU

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

ROME

CheckMate 568

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

LUNGVIR

Luscid

EMERGE

Neoadjuvant Immunotherapy in Brain Metastases

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

TOP1201 IPI

MAPS2

INITIATE

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

SQUINT

NIBIT-ML1

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

ICE

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer